Further info on the Trucheck-intelli Cancer test

A positive result means that CTCs have been found in your blood. The test results will indicate the location for the select type of cancers with high accuracy, and in other cancers the tissue of origin can be identified with reasonable accuracy. This means we can tell you where the cancer started developing in your body.

With any positive result, a member of the clinical team will call you personally to discuss your results, what they mean and guide you on your next steps which would include a referral. We have an established patient pathway if you get a positive result.

A negative result means that at the time of the test there were no detectable cancer cells for the cancers included within the test, circulating in your blood. It does not mean that you will never develop cancer. For any cancers not covered by the test, no inference should be drawn from a negative result.

Although the fundamental premise of both the Grail and the TruCheck test is to identify the presence of early stage cancers in the blood, the technology is quite different. Grail relies on a process where the detection of cells is indirect, where the TruCheck test uses immunocytochemistry to directly detect actual Circulating Tumour Cells (CTCs). Grail, unlike TruCheck, is not available in the UK as a private test and is currently only being conducted as part of an NHS Clinical trial. The supporting medical trial data for Grail has not been as strong in the detection for early-stage cancers in comparison to TruCheck, and so the overall cancer pick-up rate is lower. Parking the accessibility of the tests, Goodbody have assessed both tests extensively and we have found TruCheck to be far more suitable for asymptomatic cancer screening, giving the best possible detection rates for patients.